JRJohn I. Risinger

John I. Risinger

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


John I. Risinger has a total of 33 co-authors. Here are the top co-authors by number of shared publications:

  • Andrew Berchuck

    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Duke University School of Medicine, Durham, NC

    1 shared publication
  • Bridget A. Finniff

    Uniformed Services University of the Health Sciences 10 Department of Pharmacology and Molecular Therapeutics Bethesda, Maryland

    1 shared publication
  • Chad A. Hamilton

    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Walter Reed National Military Medical Center, Bethesda, MD

    1 shared publication
  • Clifton Dalgard

    Department of Anatomy, Physiology and Genetics, Uniformed Services University of the Health Sciences, Bethesda, USA

    1 shared publication
  • Galen Hostetter

    Affiliation Pathology and Biorepository Core, Van Andel Research Institute, Grand Rapids, Michigan, United States of America

    1 shared publication
  • Gauthaman Sukumar

    Uniformed Services University of the Health Sciences 9 Center for Military Precision Health, Department of Anatomy, Physiology and Genetics Bethesda, Maryland

    1 shared publication

Latest Publications

  • Open Access

    ATR Inhibitors and Gemcitabine Synergize to Induce Cell Death in TP53 -Mutant, ATRX -Wildtype Uterine Leiomyosarcoma

    by Megan E. Doherty, Minnie Malik, Yuka Otsuka, Nicholas W. Bateman, John I. Risinger, Nicholas Pyskir, Thomas P. Conrads, Kathleen M. Darcy, G. Larry Maxwell, Satishkumar Ranganathan Ganakammal, et al.

    Inactivating mutations in TP53 and ATRX are key alterations defining the genomic landscape of uterine leiomyosarcoma, creating chronic replication stress and increasing dependency on ataxia telangiectasia and Rad3–related (ATR) kinase signaling for survival. ATR–checkpoint kinase 1 (CHK1) signaling limits the efficacy of standard-of-care gemcitabine by facilitating the stabilization of stalled replication forks and preventing lethal DNA strand breaks in checkpoint-deficient cells. In this study, we show that ATR inhibitors (ATRi; elimusertib, ceralasertib, and berzosertib) preferentially synergize with gemcitabine over docetaxel or doxorubicin, across a panel of TP53-mutant/ATRX-wildtype (WT) uterine leiomyosarcoma models. When simultaneously administered, gemcitabine/elimusertib demonstrated enhanced synergy and efficacy compared with standard-of-care gemcitabine/docetaxel (Gem/Tax). This combination benefit was absent in a TP53-WT uterine sarcoma control line, highlighting TP53 mutation status as a critical predictive biomarker. Combined gemcitabine/ATRi treatment demonstrated reciprocal potency enhancement at low-nanomolar concentrations and significantly increased apoptotic populations compared with monotherapy. Gemcitabine monotherapy induced CHK1 (S345) phosphorylation and a corresponding S-phase arrest. Elimusertib abrogated this checkpoint, transforming protective S-phase arrest into a cytotoxic response characterized by a marked increase in the sub-G1 population. This transition was driven by the inhibition of gemcitabine-induced CHK1 phosphorylation, resulting in marked accumulation of unrepaired DNA damage (γH2AX) and the induction of apoptosis as evidenced by cleaved caspase 3 expression. These findings demonstrate that elimusertib strongly potentiates gemcitabine-induced damage to kill TP53-mutant uterine leiomyosarcoma in vitro, outperforming standard Gem/Tax when concurrently administered. This combination strategy broadens the clinical utility of ATRis to uterine leiomyosarcoma harboring the prevalent TP53-mutant/ATRX-WT genotype and supports the clinical evaluation of gemcitabine/ATRi combinations as a novel therapy for uterine leiomyosarcoma.

  • Open Access

    Co-existing TP53 and ARID1A mutations promote aggressive endometrial tumorigenesis

    by Jake J. Reske, Mike R. Wilson, Jeanne Holladay, Rebecca A. Siwicki, Hilary Skalski, Shannon Harkins, Marie Adams, John I. Risinger, Galen Hostetter, Ken Lin, et al.

    TP53 and ARID1A are frequently mutated across cancer but rarely in the same primary tumor. Endometrial cancer has the highest TP53-ARID1A mutual exclusivity rate. However, the functional relationship between TP53 and ARID1A mutations in the endometrium has not been elucidated. We used genetically engineered mice and in vivo genomic approaches to discern both unique and overlapping roles of TP53 and ARID1A in the endometrium. TP53 loss with oncogenic PIK3CAH1047R in the endometrial epithelium results in features of endometrial hyperplasia, adenocarcinoma, and intraepithelial carcinoma. Mutant endometrial epithelial cells were transcriptome profiled and compared to control cells and ARID1A/PIK3CA mutant endometrium. In the context of either TP53 or ARID1A loss, PIK3CA mutant endometrium exhibited inflammatory pathway activation, but other gene expression programs differed based on TP53 or ARID1A status, such as epithelial-to-mesenchymal transition. Gene expression patterns observed in the genetic mouse models are reflective of human tumors with each respective genetic alteration. Consistent with TP53-ARID1A mutual exclusivity, the p53 pathway is activated following ARID1A loss in the endometrial epithelium, where ARID1A normally directly represses p53 pathway genes in vivo, including the stress-inducible transcription factor, ATF3. However, co-existing TP53-ARID1A mutations led to invasive adenocarcinoma associated with mutant ARID1A-driven ATF3 induction, reduced apoptosis, TP63+ squamous differentiation and invasion. These data suggest TP53 and ARID1A mutations drive shared and distinct tumorigenic programs in the endometrium and promote invasive endometrial cancer when existing simultaneously. Hence, TP53 and ARID1A mutations may co-occur in a subset of aggressive or metastatic endometrial cancers, with ARID1A loss promoting squamous differentiation and the acquisition of invasive properties.


  • MicroRNAs in endometrial cancers from black and white patients

    by G. Larry Maxwell, Yutaka Shoji, Kathleen Darcy, Tracy Litzi, Andrew Berchuck, Chad A. Hamilton, Thomas P. Conrads, John I. Risinger